CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.
Follow CRMD
CorMedix Inc (CRMD) Piotroski F-score
CorMedix Inc's Piotroski F-score for fiscal 2025 cannot be worked out: needs three fiscal years.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 4 | (1.00) |
| FY2021 | 5 | 1.00 |
| FY2020 | 4 | 1.00 |
| FY2019 | 3 | (1.00) |
| FY2018 | 4 | 0.00 |
| FY2017 | 4 | 1.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 34.51% | — | Pass | 1 |
| Positive operating cash flow | 175.05m | (50.61m) | Pass | 1 |
| Rising return on assets | 34.51% | — | n/a | — |
| Cash flow above net income | 11.99m | (32.68m) | Pass | 1 |
| Falling long-term leverage | 0.31 | — | n/a | — |
| Rising current ratio | 2.11 | 3.39 | Fail | 0 |
| No new shares issued | 72,034,000 | 58,872,000 | Fail | 0 |
| Rising gross margin | 88.46% | 92.66% | Fail | 0 |
| Rising asset turnover | 0.66 | — | n/a | — |
| Piotroski F-score | n/a — needs three fiscal years | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ZVRA Zevra Therapeutics, Inc. compare | 6 |
| DBVT DBV Technologies S.A. compare | 4 |
| PHAT Phathom Pharmaceuticals, Inc. compare | 4 |
| STTK Shattuck Labs, Inc. compare | 4 |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 2 |
| VALN Valneva SE Sponsored ADR compare | 2 |
| OLMA Olema Pharmaceuticals, Inc. compare | — |
| SGMT Sagimet Biosciences Inc. compare | — |
| CRMD CorMedix Inc | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover